Clinical trial
Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients…
NCT00083447 · Xenova Biomedix, Industry · Withdrawn
Key facts
| NCT number | NCT00083447 |
|---|---|
| Title | Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme |
| Official title | A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID™ Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme |
| Lead sponsor | Xenova Biomedix, Industry |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Glioblastoma Multiforme |
| Intervention type | Drug |
| Interventions | TransMID™ |
| Enrollment | 323 |
| Start date | May 1, 2004 |
| Primary completion | Mar 1, 2006 |
| Completion | Jun 1, 2007 |
| First posted | May 26, 2004 |
| Last update posted | Jan 7, 2009 |
| Countries | Australia, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: